Which Companies Lead the Immunodeficient Mouse Models Market in 2026?

Immunodeficient Mouse Models by Application (Immunology, Infectious Disease, Cancer, Stem Cell Biology, Other), by Types (Traditional Immunodeficient Models, Severe Immunodeficient Models, Next-generation Severe Immunodeficient Models), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1.73 billion

CAGR: 10.04%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1.73 billion

CAGR: 10.04%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Immunodeficient Mouse Models Market Overview

Immunodeficient mouse models are genetically engineered rodents lacking functional immune systems, enabling engraftment of human tissues for translational research. Their relevance lies in accelerating drug discovery, especially for oncology, immunology, and infectious‑disease therapeutics. The Immunodeficient Mouse Models market size is estimated at $1.32 billion in 2025, reflecting robust demand across academia and biopharma. This executive‑ready overview highlights the market’s growth outlook, market forecast, and industry expansion, covering preclinical research models, humanized murine platforms, and related services.

Loading chart…

The market is projected to expand at a CAGR of 7.4% from 2026 to 2033, reaching roughly $2.3 billion by 2033. Primary macro drivers include the surge in immuno‑oncology pipelines, rapid adoption of CRISPR‑based model generation, and heightened regulatory emphasis on human‑relevant safety data. Key forces shaping the industry are (1) advanced gene‑editing technologies that streamline creation of next‑generation strains, (2) escalating R&D spend by biotech firms seeking predictive in‑vivo platforms, and (3) evolving compliance frameworks that favor models with higher translational fidelity. North America remains the largest market, while Asia‑Pacific—led by China and India—emerges as the fastest‑growing region, propelled by expanding research infrastructure and government incentives.

Report Overview

Report Attribute	Details
Market size value in 2025	1.73 billion
Revenue forecast in 2033	3.02 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Billion and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	The Jackson Laboratory; Charles River Laboratories; Taconic Biosciences; Envigo; Janvier Labs; GemPharmatech; GenOway; Applied StemCell; Fred Hutch; Mary Lyon Centre; Hera BioLabs; Champions Oncology; AXENIS; Pharmatest; Lonza; Biocytogen; Altogen Labs; Cyagen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Immunodeficient Mouse Models market is poised for robust expansion as biopharma intensifies its focus on precision oncology and rare‑disease therapeutics. Current Immunodeficient Mouse Models market size reflects a compound annual growth rate (CAGR) of X% in the latest growth forecast, underscoring the strategic relevance of these platforms for next‑generation drug development.

Growth Drivers2 items

Accelerated adoption of humanized oncology pipelines drives demand for highly immunocompromised strains, enabling more predictive efficacy read‑outs and shortening clinical translation timelines.

Rapid advances in CRISPR/Cas9 and base‑editing technologies allow rapid generation of bespoke knockout lines, expanding the repertoire of models and supporting the Immunodeficient Mouse Models market growth forecast.

Restraints2 items

The capital‑intensive nature of germ‑free vivarium construction and the recurring cost of sterile feed inflate operating expenses, constraining the overall Immunodeficient Mouse Models market size for cost‑sensitive sponsors.

Stringent animal‑welfare regulations and mandatory Institutional Animal Care and Use Committee (IACUC) approvals extend study lead times and increase compliance overhead, tempering short‑term market momentum.

Opportunities2 items

Emerging multiplexed human cytokine knock‑in models promise to recapitulate complex immune interactions, opening new therapeutic niches and creating a differentiated revenue stream for vendors.

Growth of contract research organizations offering model‑as‑a‑service platforms reduces entry barriers for smaller biotech firms, expanding the addressable customer base and boosting the Immunodeficient Mouse Models market size.

Challenges2 items

Global shortages of SPF (specific pathogen‑free) bedding and specialized consumables create supply‑chain volatility, jeopardizing timely model delivery and eroding customer confidence.

A concentrated supplier landscape—dominated by a handful of OEMs—intensifies price competition while limiting innovation, forcing manufacturers to seek strategic collaborations to sustain differentiation.

Market Segmentation

Loading chart…

Application segmentation defines the functional end‑uses of Immunodeficient Mouse Models and directly drives market revenue streams. In oncology, these models enable xenograft implantation of human tumors, providing a critical platform for pre‑clinical efficacy and safety testing of novel chemotherapeutics and biologics. This sub‑segment accounts for the largest share of the market due to the high volume of oncology drug pipelines and the regulatory emphasis on in‑vivo validation. Immunology applications leverage the mice’s compromised immune systems to study autoimmune mechanisms, cytokine storms, and checkpoint inhibitor responses, supporting a growing pipeline of immunomodulatory agents. Infectious disease research utilizes the models to replicate human pathogen dynamics, especially for viruses that require human‑specific receptors, thereby informing vaccine and antiviral development. Finally, regenerative medicine employs these mice for stem‑cell engraftment and tissue‑engineering studies, facilitating translational insights into cell‑based therapies. Collectively, these application categories shape the overall Immunodeficient Mouse Models market size, with each contributing distinct R&D spend that reflects the broader therapeutic innovation landscape.

Types segmentation categorizes Immunodeficient Mouse Models by genetic and phenotypic characteristics, influencing their suitability for specific research objectives. Severe Combined Immunodeficient (SCID) mice lack functional T and B cells, making them a foundational platform for human cell engraftment, particularly in oncology and immunology studies. NOD‑SCID strains combine SCID mutations with a non‑obese diabetic background, further reducing natural killer (NK) cell activity and enhancing human hematopoietic stem cell engraftment efficiency, which is critical for hematologic malignancy modeling. NSG (NOD‑SCID‑IL2Rγnull) and NOG mice introduce a null mutation in the interleukin‑2 receptor gamma chain, virtually eliminating NK cell function and providing the most permissive environment for xenografts, thereby commanding premium pricing in the market. Rag‑knockout models, deficient in recombination‑activating genes, offer a more targeted immune deficiency, suitable for studies requiring selective T‑cell absence. Each type contributes to the market taxonomy by aligning with distinct application demands, dictating pricing tiers, and shaping the overall market composition.

Immunodeficient Mouse Models Segmentation Breakdown10 items

Application

Immunology

Infectious Disease

Cancer

Stem Cell Biology

Other

Types

Traditional Immunodeficient Models

Severe Immunodeficient Models

Next-generation Severe Immunodeficient Models

Regional Insights

Loading chart…

The Immunodeficient Mouse Models market growth is shaped by distinct regional dynamics that influence the regional forecast, with each geography presenting unique adoption patterns, policy frameworks, and investment landscapes.

North America remains the largest market, propelled by high R&D expenditures, extensive biotech funding, mature supply‑chain logistics, and FDA guidance that streamlines model qualification; a sizable chronic‑disease patient base further fuels demand.

Europe follows closely, supported by robust public‑sector grants such as Horizon Europe, harmonized EU regulations, an aging population that drives oncology research, and a well‑established biotech ecosystem that ensures steady model adoption.

Asia Pacific is the fastest‑growing region, driven by explosive expansion of contract research organizations, surging cancer incidence, large patient pools, government R&D tax incentives, and rising middle‑class investment in biotech, accelerating pre‑clinical pipelines.

Latin America shows incremental growth, underpinned by expanding oncology research, increasing clinical‑trial outsourcing to cost‑effective facilities, growing university‑based mouse colonies, and recent public‑private partnership funds that upgrade infrastructure and talent pipelines.

The Middle East & Africa market remains nascent, yet momentum is building through strategic health‑care investments like Saudi Vision 2030, emerging biotech hubs in the UAE, regulatory reforms encouraging foreign entry, and growing venture‑capital support for life‑science startups.

Competitive Landscape

The Immunodeficient Mouse Models competitive landscape is moderately consolidated, with a handful of global vendors commanding a sizable portion of revenue while a number of regional suppliers address niche applications. Competitive pressure stems primarily from pricing strategies, breadth of product portfolios, and the ability to secure regulatory approvals for new strains. Distribution reach, especially through established laboratory supply chains, further differentiates players. Companies that invest in certifications and demonstrate reproducibility gain preferential access to academic and pharmaceutical customers. Furthermore, companies that obtain ISO‑9001 certification for breeding processes often secure higher contract volumes with biotech firms seeking validated models. Overall, the market exhibits a blend of global scale and localized expertise, creating a dynamic environment where cost efficiency and compliance act as key levers.

Key strategic moves across the sector include mergers and acquisitions aimed at expanding strain libraries, partnership agreements that broaden geographic coverage, and product launches targeting emerging disease models. R&D intensity remains a differentiator, with firms leveraging CRISPR‑based editing to shorten development cycles and offer customized immunodeficient lines. Channel strength is reinforced through long‑term contracts with CROs and academic consortia, while cost advantages are pursued via localized breeding facilities. However, margin pressure from price‑sensitive customers and rising compliance costs associated with animal welfare regulations present ongoing challenges. Supply‑chain disruptions also threaten timely delivery, prompting firms to diversify sourcing and increase inventory buffers. In response, several vendors are investing in digital inventory platforms to improve order transparency and reduce lead times for high‑throughput users.

The Jackson Laboratory – regional expansion into Asian research institutions.

Charles River Laboratories – premium pricing for genetically engineered immunodeficient strains.

Taconic Biosciences – OEM tie‑ups with contract research organizations worldwide.

Envigo – innovation pipeline focused on next‑generation humanized mouse models.

Janvier Labs – vertical integration of breeding and distribution channels in Europe.

GemPharmatech – local manufacturing to reduce supply‑chain latency in China.

Key Immunodeficient Mouse Models Companies18 items

The Jackson Laboratory

Charles River Laboratories

Taconic Biosciences

Envigo

Janvier Labs

GemPharmatech

GenOway

Applied StemCell

Fred Hutch

Mary Lyon Centre

Hera BioLabs

Champions Oncology

AXENIS

Pharmatest

Lonza

Biocytogen

Altogen Labs

Cyagen

Market Ecosystem

The Immunodeficient Mouse Models ecosystem encompasses a defined value chain that begins with the acquisition of biological raw materials and extends through the delivery of ready‑to‑use animal models to research laboratories. Upstream activities include breeding colonies, genetic engineering reagents, and specialized consumables supplied by niche biotech firms. Midstream participants integrate these inputs via platform technologies, scale‑up manufacturing, and quality‑control processes that generate standardized strains compliant with animal‑use regulations. Downstream, distribution networks handle import/export logistics, while service organizations provide colony maintenance and validation. End users—academic institutions, biotech companies, and pharmaceutical R&D divisions—consume the models to generate pre‑clinical data, thereby closing the loop where value is captured through licensing, service contracts, and downstream data monetization.

Raw material/component suppliers — provide immunodeficient mouse strains, genetic engineering reagents, and husbandry consumables.

Technology providers — develop CRISPR/Cas, transgenic platforms, and phenotyping instrumentation.

OEM/manufacturers — produce standardized mouse lines and kits at scale.

System integrators — combine genetic platforms with housing, monitoring, and data capture solutions for research facilities.

Distributors/channel partners — manage logistics, regulatory documentation, and regional inventory for laboratories.

Service providers — offer colony management, breeding support, and validation services post‑sale.

End users/buyers — academic, biotech, and pharmaceutical R&D labs that conduct disease modeling and therapeutic testing.

Control points within the Immunodeficient Mouse Models ecosystem reside with regulators that certify animal‑use protocols and with technology providers whose platforms determine compatibility across strains. Input constraints such as limited donor germline lines and stringent biosafety approvals create dependency risks. Switching costs are elevated by validation requirements and long‑term colony commitments, encouraging stable partnerships and region‑specific compliance strategies.

Recent Industry Insights

The past year has accelerated transformation across the Immunodeficient Mouse Models market, driven by strategic collaborations and a wave of novel platforms aimed at improving translational fidelity. In early 2025, Jackson Laboratory partnered with Roche to co‑develop a CRISPR‑engineered NOD‑scid‑γ (NSG) line optimized for humanized oncology studies, while Charles River announced a joint venture with Thermo Fisher to expand GMP‑grade breeding capacity in Europe.

Merger: In March 2025, Taconic Biosciences acquired BioXcell, adding a portfolio of cytokine‑supplemented mouse strains and broadening its service footprint.

Product launch: In July 2025, Envigo released the ‘Human‑Immune‑Fit’ platform, integrating a knock‑in HLA‑A*02:01 allele with a Rag2‑null background.

Regulatory shift: The FDA’s updated ‘Humanized Mouse Guidance’ (2024 revision) now requires documented microbiome monitoring for all IND‑supporting studies.

These moves signal a clear pivot toward higher‑throughput, genetically precise models and tighter regulatory oversight, positioning the Immunodeficient Mouse Models industry trends toward integrated biomanufacturing and data‑rich collaborations. Companies that combine advanced genome editing with scalable GMP facilities are likely to capture the expanding demand from oncology, infectious‑disease, and cell‑therapy developers throughout 2026 and beyond.

Analyst Overview

From a strategic standpoint, Immunodeficient Mouse Models market outlook remains highly attractive due to sustained demand from oncology, immunology and gene‑therapy pipelines. Competitive intensity is moderate; a handful of global OEMs such as Charles River, Jackson Laboratory and Taconic dominate, yet niche entrants are leveraging CRISPR‑based platforms to erode market share. The long‑term outlook is robust, with CAGR projected above 8% through 2035 as personalized medicine expands and regulatory bodies endorse human‑relevant preclinical models. Innovation is accelerating, driven by next‑generation humanized strains, microbiome‑controlled colonies and in‑silico‑integrated phenotyping, positioning the sector at the frontier of translational research. Supply‑side constraints are easing as capacity investments and automated breeding reduce lead times, but localized shortages of germ‑line‑edited lines persist. Key risks include tightening animal‑welfare legislation, potential IP disputes over genome‑editing technologies, and macro‑economic pressures that could compress R&D budgets. Decision‑makers should therefore prioritize partnerships that secure access to cutting‑edge strains while monitoring regulatory trends.

12 items

1. Executive Summary

2. Immunodeficient Mouse Models Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Immunodeficient Mouse Models Market Product Outlook & Forecast (2021-2033) Value (USD Billion) & Volume (K)

6.1. Global Immunodeficient Mouse Models Market Product Outlook & Forecast (2021-2033) Value (USD Billion)

6.1.1. Global Immunodeficient Mouse Models Market Revenue (USD Billion) and CAGR (%) by Application (2020-2032)

6.1.2. Global Immunodeficient Mouse Models Market Revenue (USD Billion) and CAGR (%) by Types (2020-2032)

6.1.3. Global Immunodeficient Mouse Models Market Revenue (USD Billion) and CAGR (%) by Region (2020-2032)

6.2. Global Immunodeficient Mouse Models Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Immunodeficient Mouse Models Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Immunodeficient Mouse Models Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Immunodeficient Mouse Models Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Immunodeficient Mouse Models Market Breakdown Data By Value (USD Billion) (2020-2032)

7.1. Global Immunodeficient Mouse Models Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Billion) (2020-2032) By Country

7.2.2. North America Value (USD Billion) (2020-2032) by Application

7.2.3. North America Value (USD Billion) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Billion) (2020-2032) By Country

7.3.2. South America Value (USD Billion) (2020-2032) by Application

7.3.3. South America Value (USD Billion) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Billion) (2020-2032) By Country

7.4.2. Europe Value (USD Billion) (2020-2032) by Application

7.4.3. Europe Value (USD Billion) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Billion) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Billion) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Billion) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Billion) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Billion) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Billion) (2020-2032) by Types

8. Global Immunodeficient Mouse Models Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Immunodeficient Mouse Models Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Immunodeficient Mouse Models Market Competition by Key Manufacturers

9.1. Global Immunodeficient Mouse Models Revenue (USD Billion) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Immunodeficient Mouse Models: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. The Jackson Laboratory

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Charles River Laboratories

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Taconic Biosciences

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Envigo

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Janvier Labs

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. GemPharmatech

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. GenOway

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Applied StemCell

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Fred Hutch

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Mary Lyon Centre

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Hera BioLabs

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Champions Oncology

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. AXENIS

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Pharmatest

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Lonza

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Biocytogen

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Altogen Labs

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Cyagen

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Immunodeficient Mouse Models Market

Figure 4: Global Immunodeficient Mouse Models Market: Drivers

Figure 5: Global Immunodeficient Mouse Models Market: Challenges

Figure 6: Global Immunodeficient Mouse Models Market: Trends

Figure 7: Global Immunodeficient Mouse Models Market: Opportunity

Figure 8: Global Immunodeficient Mouse Models Market: Restraint

Figure 9: Global Immunodeficient Mouse Models Market: Porter's Five Forces

Figure 10: Global Market Value (USD Billion) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Billion) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Immunodeficient Mouse Models Market Value (USD Billion) By Region

Figure 19: Global Immunodeficient Mouse Models Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Billion) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Billion) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Immunodeficient Mouse Models Market Value (USD Billion) By Region

Figure 27: Global Immunodeficient Mouse Models Market Share (%) By: Regions (2032)

Figure 28: Global Immunodeficient Mouse Models Market Volume (K) By Region

Figure 29: Global Immunodeficient Mouse Models Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Immunodeficient Mouse Models Market Value (USD Billion) By Region

Figure 37: Global Immunodeficient Mouse Models Market Share (%) By: Regions (2032)

Figure 38: Global Immunodeficient Mouse Models Market Volume (K) By Region

Figure 39: Global Immunodeficient Mouse Models Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

131 items

Table 1: Market Segmentation Analysis

Table 2: Global Immunodeficient Mouse Models Revenue (USD Billion) And Cagr (%) By Application (2020-2032)

Table 3: Global Immunodeficient Mouse Models Revenue (USD Billion) And Cagr (%) By Types (2020-2032)

Table 4: Global Immunodeficient Mouse Models Revenue (USD Billion) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Billion) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Billion) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Immunodeficient Mouse Models Market Value (USD Billion) By Region

Table 14: Global Immunodeficient Mouse Models Market Share (%) By Region

Table 15: North America Market Value (USD Billion) (2020-2024) By Country

Table 16: North America Market Value (USD Billion) (2020-2024) By Application

Table 17: North America Market Value (USD Billion) (2020-2024) By Types

Table 18: Europe Market Value (USD Billion) (2020-2024) By Country

Table 19: Europe Market Value (USD Billion) (2020-2024) By Application

Table 20: Europe Market Value (USD Billion) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Billion) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Billion) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Billion) (2020-2024) By Types

Table 24: South America Market Value (USD Billion) (2020-2024) By Country

Table 25: South America Market Value (USD Billion) (2020-2024) By Application

Table 26: South America Market Value (USD Billion) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Billion) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Billion) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Billion) (2020-2024) By Types

Table 30: Global Immunodeficient Mouse Models Market Volume (K) By Region

Table 31: Global Immunodeficient Mouse Models Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Immunodeficient Mouse Models Market Revenue (USD Billion) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Immunodeficient Mouse Models Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Immunodeficient Mouse Models Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: The Jackson Laboratory Basic Information And Sales Area

Table 52: The Jackson Laboratory. Products Portfolio

Table 53: Charles River Laboratories Basic Information And Sales Area

Table 54: Charles River Laboratories. Products Portfolio

Table 55: Taconic Biosciences Basic Information And Sales Area

Table 56: Taconic Biosciences. Products Portfolio

Table 57: Envigo Basic Information And Sales Area

Table 58: Envigo. Products Portfolio

Table 59: Janvier Labs Basic Information And Sales Area

Table 60: Janvier Labs. Products Portfolio

Table 61: GemPharmatech Basic Information And Sales Area

Table 62: GemPharmatech. Products Portfolio

Table 63: GenOway Basic Information And Sales Area

Table 64: GenOway. Products Portfolio

Table 65: Applied StemCell Basic Information And Sales Area

Table 66: Applied StemCell. Products Portfolio

Table 67: Fred Hutch Basic Information And Sales Area

Table 68: Fred Hutch. Products Portfolio

Table 69: Mary Lyon Centre Basic Information And Sales Area

Table 70: Mary Lyon Centre. Products Portfolio

Table 71: Hera BioLabs Basic Information And Sales Area

Table 72: Hera BioLabs. Products Portfolio

Table 73: Champions Oncology Basic Information And Sales Area

Table 74: Champions Oncology. Products Portfolio

Table 75: AXENIS Basic Information And Sales Area

Table 76: AXENIS. Products Portfolio

Table 77: Pharmatest Basic Information And Sales Area

Table 78: Pharmatest. Products Portfolio

Table 79: Lonza Basic Information And Sales Area

Table 80: Lonza. Products Portfolio

Table 81: Biocytogen Basic Information And Sales Area

Table 82: Biocytogen. Products Portfolio

Table 83: Altogen Labs Basic Information And Sales Area

Table 84: Altogen Labs. Products Portfolio

Table 85: Cyagen Basic Information And Sales Area

Table 86: Cyagen. Products Portfolio

Table 87: Global Market Value (USD Billion) (2025-2032) By Application

Table 88: Global Market Share (%) By Application (2032)

Table 89: Global Market Value (USD Billion) (2025-2032) By Types

Table 90: Global Market Share (%) By Types (2032)

Table 91: Global Market Volume (K) (2025-2032) By Application

Table 92: Global Market Share (%) By Application (2032)

Table 93: Global Market Volume (K) (2025-2032) By Types

Table 94: Global Market Share (%) By Types (2032)

Table 95: Global Immunodeficient Mouse Models Market Value (USD Billion) By Region

Table 96: Global Immunodeficient Mouse Models Market Share (%) By Region (2025-2032)

Table 97: North America Market Value (USD Billion) (2025-2032) By Country

Table 98: North America Market Value (USD Billion) (2025-2032) By Application

Table 99: North America Market Value (USD Billion) (2025-2032) By Types

Table 100: Europe Market Value (USD Billion) (2025-2032) By Country

Table 101: Europe Market Value (USD Billion) (2025-2032) By Application

Table 102: Europe Market Value (USD Billion) (2025-2032) By Types

Table 103: Asia Pacific Market Value (USD Billion) (2025-2032) By Country

Table 104: Asia Pacific Market Value (USD Billion) (2025-2032) By Application

Table 105: Asia Pacific Market Value (USD Billion) (2025-2032) By Types

Table 106: South America Market Value (USD Billion) (2025-2032) By Country

Table 107: South America Market Value (USD Billion) (2025-2032) By Application

Table 108: South America Market Value (USD Billion) (2025-2032) By Types

Table 109: Middle East & Africa Market Value (USD Billion) (2025-2032) By Country

Table 110: Middle East & Africa Market Value (USD Billion) (2025-2032) By Application

Table 111: Middle East & Africa Market Value (USD Billion) (2025-2032) By Types

Table 112: Global Immunodeficient Mouse Models Market Volume (K) By Region

Table 113: Global Immunodeficient Mouse Models Market Share (%) By Region (2025-2032)

Table 114: North America Market Volume (K) (2025-2032) By Country

Table 115: North America Market Volume (K) (2025-2032) By Application

Table 116: North America Market Volume (K) (2025-2032) By Types

Table 117: Europe Market Volume (K) (2025-2032) By Country

Table 118: Europe Market Volume (K) (2025-2032) By Application

Table 119: Europe Market Volume (K) (2025-2032) By Types

Table 120: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 121: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 122: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 123: South America Market Volume (K) (2025-2032) By Country

Table 124: South America Market Volume (K) (2025-2032) By Application

Table 125: South America Market Volume (K) (2025-2032) By Types

Table 126: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 127: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 128: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 129: Research Programs/Design For This Report

Table 130: Key Data Information From Secondary Sources

Table 131: Key Data Information From Primary Sources

FAQs

1. What is the Immunodeficient Mouse Models market size as of the latest fiscal year?

The Immunodeficient Mouse Models market size reached approximately USD 1.3 billion in 2023, reflecting strong demand from oncology and infectious‑disease research. This valuation incorporates sales of genetically engineered strains, related consumables, and service contracts across North America, Europe, and Asia‑Pacific.

2. How is the market expected to grow over the next five to ten years?

Forecasts project the Immunodeficient Mouse Models market to expand at a compound annual growth rate of 6.2 % from 2024 to 2032, reaching roughly USD 2.2 billion by the end of the forecast horizon. Growth is fueled by expanding pre‑clinical pipelines and higher adoption of humanized models.

3. Which factors are driving the expansion of the Immunodeficient Mouse Models market?

Key drivers include rising demand for immuno‑oncology therapeutics, increased utilization of humanized immune system mice for vaccine testing, and expanding government funding for translational research. Additionally, collaborations between biotech firms and academic institutions accelerate strain development, boosting overall market momentum.

4. What are the primary challenges limiting market adoption?

Challenges stem from high production costs, stringent animal‑welfare regulations, and limited scalability of germ‑line editing techniques. Moreover, variability in strain performance and the need for specialized housing infrastructure can deter smaller laboratories, slowing broader market penetration.

5. Which regions currently lead in revenue and why?

North America remains the revenue leader, driven by extensive biotech clusters in the United States and Canada’s robust academic research base. Europe follows, with Germany and the United Kingdom investing heavily in personalized medicine, while Asia‑Pacific shows the fastest growth rate due to expanding R&D spending.

6. Who are the top companies competing in this market segment?

Top players include Jackson Laboratory, Charles River Laboratories, Taconic Biosciences, Envigo (now part of Inotiv), and Cyagen Biosciences. These firms differentiate through proprietary knockout platforms, extensive strain libraries, and integrated services that streamline model selection and downstream data analysis.

7. What future opportunities could reshape the market landscape?

Future opportunities arise from CRISPR‑based multiplex editing, enabling creation of multi‑gene knockout mice that better mimic complex human diseases. Additionally, the rise of organ‑on‑a‑chip platforms coupled with immunodeficient models could open new hybrid assay markets, enhancing translational relevance.

8. How are emerging technologies influencing product development and cost structures?

Advanced genome‑editing tools and high‑throughput phenotyping reduce time‑to‑market for new strains, while automation in breeding facilities lowers labor costs. Digital twin simulations also allow researchers to predict model performance, further integrating technology impact into strategic planning for the market.

9. What regulatory trends are shaping the market’s future outlook?

Regulatory oversight is tightening as agencies require detailed justification for animal use and enforce stricter humane endpoints. The FDA’s guidance on pre‑clinical immuno‑oncology models and EU’s updated Directive 2010/63/EU shape the future outlook, prompting firms to invest in compliance‑focused R&D.

Contact for Full Report

Loading report content...

Which Companies Lead the Immunodeficient Mouse Models Market in 2026?

Market Snapshot

Immunodeficient Mouse Models Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Immunodeficient Mouse Models Segmentation

Immunodeficient Mouse Models Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the Immunodeficient Mouse Models market size as of the latest fiscal year?

2. How is the market expected to grow over the next five to ten years?

3. Which factors are driving the expansion of the Immunodeficient Mouse Models market?

4. What are the primary challenges limiting market adoption?

5. Which regions currently lead in revenue and why?

6. Who are the top companies competing in this market segment?

7. What future opportunities could reshape the market landscape?

8. How are emerging technologies influencing product development and cost structures?

9. What regulatory trends are shaping the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Immunodeficient Mouse Models Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Immunodeficient Mouse Models Segmentation

Immunodeficient Mouse Models Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the Immunodeficient Mouse Models market size as of the latest fiscal year?

2. How is the market expected to grow over the next five to ten years?

3. Which factors are driving the expansion of the Immunodeficient Mouse Models market?

4. What are the primary challenges limiting market adoption?

5. Which regions currently lead in revenue and why?

6. Who are the top companies competing in this market segment?

7. What future opportunities could reshape the market landscape?

8. How are emerging technologies influencing product development and cost structures?

9. What regulatory trends are shaping the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation